SLC7A11 and neoplasm: Moreover, in vivo experiments have shown that the deletion of the SLC7A11 gene in T cells has no clear impact on their antitumor response, while the knockout of the SLC7A11 gene in tumor cells can enhance the efficacy of tumor immunotherapy.